Volv was founded to allow customers to exploit latest developments in technology and data science to generate unique and powerful insights from data. Our mission is to speed science, reduce the cost of healthcare, and so enhance the economic output and well-being for all.
Using the flagship product, inTrigue, Volv finds undiagnosed and misdiagnosed rare disease patients from electronic healthcare records up to eight years earlier than traditional approaches.
Within3 invented a better way for life sciences companies to have conversations with the people who matter most—from doctors to patients to payers, and more. Our virtual engagement platform gives stakeholders the freedom to communicate anytime, anywhere, on any device. With tools for meaningful discussions and a dedicated client success team on every project, most Within3 projects achieve 100% stakeholder participation. To learn more and request a demo, visit www.within3.com.
Angelini Pharma is an international pharmaceutical company, part of the Italian privately-owned Angelini Industries. Angelini Pharma is committed to finding health solutions and helping patients in the areas of Brain Health, Rare Diseases and Consumer Healthcare. Angelini Pharma operates directly in 25 countries employing almost 3,000 people and commercializes its products in more than 50 countries through strategic alliances with leading pharmaceutical groups.
A London-based, data-led medtech company accelerating the diagnosis of rare and hard-to-diagnose diseases, enabling faster, more targeted access to treatment & trials. Mendelian is a recipient of the UK’s AI Award, and is trailing their technology across the NHS where they are deploying 40 rare disease algorithms. Mendelian partners with pharmaceutical companies to develop tools focused on their disease indications.
